William Lewis Sells 10,699 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 10,699 shares of Insmed stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the completion of the transaction, the chief executive officer owned 301,185 shares in the company, valued at approximately $43,361,604.45. This represents a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

William Lewis also recently made the following trade(s):

• On Monday, April 6th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $163.22, for a total transaction of $1,746,290.78.
• On Thursday, March 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $143.52, for a total transaction of $1,535,520.48.
• On Thursday, March 5th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $146.03, for a total transaction of $1,562,374.97.
• On Thursday, February 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $150.97, for a total transaction of $1,615,228.03.
• On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The shares were sold at an average price of $147.79, for a total transaction of $1,979,794.84.
• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The shares were sold at an average price of $156.34, for a total transaction of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $158.93, for a total transaction of $1,700,392.07.

Insmed Trading Up 1.2%

NASDAQ INSM opened at $144.48 on Friday. Insmed, Inc. has a one year low of $63.81 and a one year high of $212.75. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The firm’s fifty day moving average is $149.95 and its two-hundred day moving average is $167.47. The firm has a market cap of $31.19 billion, a PE ratio of -22.54 and a beta of 1.10.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm had revenue of $263.84 million for the quarter, compared to analyst estimates of $263.97 million. During the same quarter last year, the firm earned ($1.32) earnings per share. The company’s revenue was up 152.6% compared to the same quarter last year. Analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

INSM has been the topic of a number of recent analyst reports. Jefferies Financial Group initiated coverage on shares of Insmed in a research note on Monday, March 16th. They set a “buy” rating and a $228.00 price target on the stock. Morgan Stanley upgraded shares of Insmed from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $166.00 to $212.00 in a research note on Monday, March 30th. Truist Financial set a $205.00 price target on shares of Insmed in a research note on Monday, January 12th. Wells Fargo & Company dropped their price target on shares of Insmed from $208.00 to $175.00 and set an “overweight” rating on the stock in a research note on Monday, March 23rd. Finally, Barclays boosted their price target on shares of Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $213.23.

Institutional Trading of Insmed

A number of institutional investors have recently added to or reduced their stakes in the stock. PKO Investment Management Joint Stock Co boosted its holdings in Insmed by 4.4% during the first quarter. PKO Investment Management Joint Stock Co now owns 11,800 shares of the biopharmaceutical company’s stock worth $1,930,000 after buying an additional 500 shares in the last quarter. Values First Advisors Inc. boosted its holdings in Insmed by 7.1% during the first quarter. Values First Advisors Inc. now owns 2,203 shares of the biopharmaceutical company’s stock worth $360,000 after buying an additional 146 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Insmed by 105.4% during the first quarter. SG Americas Securities LLC now owns 137,149 shares of the biopharmaceutical company’s stock worth $22,427,000 after buying an additional 70,387 shares in the last quarter. KRS Capital Management LLC purchased a new stake in Insmed during the first quarter worth about $203,000. Finally, Hsbc Holdings PLC boosted its holdings in Insmed by 8,052.6% during the fourth quarter. Hsbc Holdings PLC now owns 123,267 shares of the biopharmaceutical company’s stock worth $21,493,000 after buying an additional 121,755 shares in the last quarter.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.